subject: Aarkstore Enterprise---global Cancer Drugs Market 2009-2013 [print this page] The cancer drugs represent a large potential on the therapeutic market. Cancer is the second leading cause of death worldwide after cardiovascular diseases. According to World Heath Organization (WHO), 12 million cancer deaths are likely to occur worldwide, by 2030. Further, the adoption of unhealthy lifestyles choices such as increased use of tobacco, alcohol, and rise in obesity rate in the underdeveloped and developing countries are important factors for the cause of this disease.
Owing to the growing number of cancer-related diseases, there is an intense interest towards cancer drugs research. Many companies (pharmaceutical and biotechnology) are focusing on developing advanced cancer drugs for targeted therapy. Besides, many domestic companies have also increased their focus on R&D capabilities to develop effective cancer treatment for breast, prostate, colon, and pancreatic cancers. Over the next few years, the market is set to witness launch of advanced cancer drugs and entry of new players. Thus, intensifying competition in this industry in the development and marketing of cancer drugs.
The significant advancements in newer cancer drugs and benefits of effective treatment of various cancers are likely to boost this market. Also, the increasing prevalence of cancer cases and the subsequent need for effective means of treatment offer potential growth opportunity. Further, the enhanced focus on tailored drug delivery in cancer treatment coupled with benefits of molecular biomarkers in drug discovery are likely to support growth in the Cancer Drugs market.
This report highlights the scope of the Global Cancer Drugs market 2009-2013, along with trends, drivers, growth inhibitors and a few major vendors in the market.
